



Pseudomonas aeruginosa induces vascular endothelial growth factor synthesis in airway epithelium *in vitro* and *in vivo*

C. Martin^{*,#}, G. Thévenot^{*}, S. Danel^{*,#}, J. Chapron^{*,#}, A. Tazi^{*,1}, J. Macey^{*},
D.J. Dusser^{*,#}, I. Fajac^{*,#} and P-R. Burgel^{*,#}

ABSTRACT: *Pseudomonas aeruginosa* (PA) airway infection and bronchial blood vessel proliferation are features of bronchiectasis. Because vascular endothelial growth factor (VEGF)-A regulates angiogenesis, we hypothesised that PA infection induces VEGF synthesis in epithelium and peribronchial angiogenesis. Because epidermal growth factor receptor (EGFR) activation regulates VEGF synthesis in cancer, we also evaluated the roles of EGFR.

Airway epithelial cells were incubated for 24 h with PA supernatants and VEGF concentrations were measured in culture medium by ELISA. C57BL/6N mice were instilled intratracheally with sterile agarose beads or with agarose beads coated with the PA strain PAO1 (mean \pm SEM $6 \times 10^5 \pm 3 \times 10^5$ cfu·animal⁻¹), with or without the EGFR inhibitor AG1478 (12.5 mg·kg⁻¹·day⁻¹ intraperitoneally). Epithelial immunostaining for VEGF and phosphorylated EGFR, and peribronchial vascularity, were quantified using morphometric analysis. VEGF expression was further assessed by western blot in mouse lung homogenates.

PA supernatants induced dose-dependent VEGF synthesis in cultured airway epithelial cells, effects which were prevented by EGFR antagonists. In mice, persistent PAO1 infection increased immunostaining for VEGF and phosphorylated EGFR in airway epithelium, and resulted in increased peribronchial vascularity within 7 days. These effects were reduced by EGFR inhibition.

Persistent PA infection induced VEGF synthesis in airway epithelium and peribronchial angiogenesis, at least in part *via* EGFR-dependent mechanisms.

KEYWORDS: Airway epithelium, angiogenesis, bacterial infection, epidermal growth factor receptor, vascular endothelial growth factor

Bronchiectasis is defined as persistent or recurrent bronchial sepsis related to irreversibly damaged and dilated bronchi [1, 2]. *Pseudomonas aeruginosa* (PA) is one of the most frequently isolated pathogens from the lower respiratory tract in bronchiectasis [3]. Bronchiectasis is associated with bronchial angiogenesis (the generation of new blood vessels from existing bronchial vessels) [4, 5], but the mechanisms underlying this abnormal bronchial angiogenesis are unknown.

Vascular endothelial growth factor (VEGF)-A appears to be a key angiogenic mediator [5]. It is a vascular endothelial mitogen for arteries and veins and it regulates vascular permeability by inducing the fenestration in endothelial cells [6]. VEGF is synthesised by various respiratory cells, including

airway epithelial cells [7], and BALUK *et al.* [8] have shown that its expression in airway epithelium was sufficient to trigger tracheal angiogenesis in mice. Various cytokines, such as interleukin-1 and tumour necrosis factor- α , increased the expression of VEGF in airway epithelial cells [9], suggesting that infection and inflammation may trigger VEGF synthesis and angiogenesis.

Our aim was to study the involvement of persistent bronchial infection in the development of bronchial angiogenesis in experimental models relevant to bronchiectasis. We first studied VEGF synthesis *in vitro* in airway epithelial cells upon incubation with PA bacterial products. As there is no animal model known to develop bronchiectasis, we used a mouse model of prolonged bronchial infection created by intratracheal instillation of

AFFILIATIONS

*Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, UPRES EA 2511, Paris, #Service de Pneumologie et Service de Physiologie, and ¹Service de Bactériologie, Hôpital Cochin, AP-HP, Paris, France.

CORRESPONDENCE

P-R. Burgel
Hôpital Cochin
Service de Pneumologie
27 rue du Faubourg St Jacques
75014 Paris
France
E-mail: pierre-regis.burgel@cch.aphp.fr

Received:

Aug 22 2010
Accepted after revision:
Mar 02 2011
First published online:
Mar 24 2011

This article has supplementary material accessible from www.erj.ersjournals.com
For editorial comments, see page 758.

European Respiratory Journal
Print ISSN 0903-1936
Online ISSN 1399-3003

PA-coated agarose beads [10] to study airway VEGF expression and peribronchial vasculature. Because recent evidence suggested that various infectious stimuli in the airways lead to activation of the epidermal growth factor receptor (EGFR) [11] and because EGFR has been shown to be pro-angiogenic, albeit in tumours [12], we further studied *in vitro* and in our mouse model whether EGFR could be involved in PA-induced VEGF synthesis and angiogenesis.

METHODS

In vitro experiments

NCI-H292 (human pulmonary mucocarcinoma) and BEAS-2B (non-tumorigenic human bronchial epithelial) cells were cultured as described in the online supplementary material. Primary cultures of airway epithelial cells, a kind gift of A. Coste (Dept of Otolaryngology – Head and Neck Surgery, Hôpital Intercommunal de Créteil, Créteil, France), were obtained from three patients undergoing surgery for idiopathic nasal polyposis and were cultured as previously described [13].

For preparation of PA supernatants, bacteria were grown in tryptic soy broth dialysate (TSBD) medium with aeration at 37°C to late log phase. The broth cultures were then centrifuged at 10,000 rpm for 50 min [14]. Supernatants were harvested and kept at -80°C until used.

To assess the dose-dependent effect of the laboratory PA strain PAO1 on VEGF synthesis, confluent epithelial cells were incubated in the presence of PAO1 supernatants (dilutions 1:32 to 1:8 in cell culture medium) for 24 h. Supernatants of six strains of PA (three nonmucoid and three mucoid; dilution 1:8) obtained from the sputum of cystic fibrosis patients were also studied. In selected studies, cells were pretreated with inhibitors or with antibodies (Ab) for 30 min before exposure to PA supernatants. The following products were used: AG1478 (10^{-5} M; Calbiochem, Nottingham, UK), a selective inhibitor of EGFR tyrosine kinase; AG9 (10^{-5} M; Calbiochem), an inactive analogue of AG1478; and an EGFR-neutralising Ab (Ab-3, C225, $4 \mu\text{g}\cdot\text{mL}^{-1}$; Calbiochem). Concentrations of inhibitors and Abs were selected based on previous literature [15]. After 24-h incubation in the presence of PA supernatants, cell culture media were harvested and concentrations of immunoreactive VEGF were measured by ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's protocol. Each sample was measured in duplicate.

Animal studies

Preparation of sterile and PAO1-coated agarose beads

Sterile agarose beads and agarose beads coated with the PA strain PAO1 were prepared according to slight modifications of the method described by VAN HEECKEREN and SCHLUCHTER [10]. Briefly, 1 mL of PAO1 suspension ($5.4 \times 10^9 \pm 1.9 \times 10^9$ cfu) was mixed with 8.5 mL of 50°C pre-warmed 2% agarose type XII (Sigma, St Louis, MO, USA) in PBS, and 0.5 mL of Indian ink (to allow bead visualisation in tissue). This agarose-broth mixture was added to 150 mL of heavy mineral oil (Sigma) equilibrated at 50°C. The mixture was stirred for 6 min at room temperature, then cooled at 4°C with continuous stirring for 20 min and finally centrifuged for 20 min at $3,200 \times g$. The beads were washed three times with 10 mL of 0.5%, 0.25% and finally no sodium deoxycholate (Sigma) in PBS. The rate of stirring and cooling was determined to obtain beads with a median size of

300 μm . Bead size was further secured by filtration through 400- and 300- μm filters. Beads were diluted in sterile PBS to obtain a 20% bead concentration. To estimate the number of bacteria entrapped in beads, aliquots of bead suspensions were homogenised, and were plated on trypticase soy agar for bacterial culture. Control beads were prepared as described above without the addition of PA and these beads were found to be sterile when cultured on trypticase soy agar.

Mouse infection model

Female C57BL/6N mice aged 6 weeks were purchased from Harlan (Gannat, France) and housed in conventional conditions. Mice were anaesthetised with a ketamine/xylazine ($15/2 \text{ mg}\cdot\text{mL}^{-1}$) solution administered intraperitoneally (0.1 mL per 10 g of weight), and were intubated with a 20-g cannula attached to a 1-mL syringe. A 150- μL inoculum of sterile or PAO1-coated beads (containing mean \pm SEM $6 \times 10^5 \pm 3 \times 10^5$ cfu) was instilled through the cannula into the trachea. In selected experiments, mice were treated intraperitoneally with the selective inhibitor of EGFR tyrosine kinase, AG1478 ($12.5 \text{ mg}\cdot\text{kg}^{-1}\cdot\text{day}^{-1}$) [16], or with vehicle, 24 h before instillation of PAO1-coated beads and daily until sacrifice. Mice were sacrificed at day 1 and day 7. To confirm that persistent airway infection was present at day 7 after instillation of PAO1-coated beads, animals were sacrificed and 10-fold dilutions of left lung homogenates were plated on trypticase soy agar. Bacterial counts at day 7 were $8.4 \times 10^2 \pm 3.8 \times 10^2$ cfu $\cdot\text{lung}^{-1}$ ($n=14$ animals), confirming that persistent airway infection occurred in our model. No bacteria were detected in lung homogenates of animals that were instilled with sterile beads (data not shown). The study was performed in accordance with the European Community Guidelines and complied with the procedures of our Institut Fédératif de Recherche (Paris, France).

Immunohistochemical staining and morphometric analysis

For histological analysis, lungs were removed after flushing 4% paraformaldehyde through the right heart, and were fixed in 4% paraformaldehyde and included in paraffin. 5- μm paraffin sections were prepared and stained as described previously [17]. The following primary Abs were used: a polyclonal rabbit Ab raised against the N-terminus of VEGF-A (A-20, dilution 1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA); a polyclonal goat Ab raised against the phosphorylated (activated) EGFR (dilution 1:50, sc-16803; Santa Cruz Biotechnology); and a polyclonal rabbit Ab raised against the endothelial marker von Willebrand factor (vWF; Dako, Glostrup, Denmark) to identify peribronchial blood vessels. Antigen unmasking by incubation with protease from *Streptomyces griseus* (0.01%, Sigma) for 20 min was required to improve the quality of staining for vWF. Biotinylated anti-rabbit or anti-goat Ab (1:200; Vector Laboratories, Burlingame, CA, USA) were used for secondary Ab and bound Ab were visualised according to standard protocols for avidin-biotin-peroxidase complex method (Elite ABC kit; Vector Laboratories). Tissue sections were counterstained with haematoxylin. Omission of primary antibodies and incubation with irrelevant immunoglobulins were used as negative controls.

Quantitative morphometric analysis was performed by two independent observers using a light microscope (Leica Microsystems, Wetzlar, Germany) connected to a computer [18].

Measurements of volumes occupied by phospho-EGFR and VEGF immunostaining in airway epithelium were performed by point counting using a grid [19, 20]. Volumes occupied by positively stained cells were expressed per volume of epithelium (as a percentage). For each animal, 40 randomly selected high power fields (400 \times) of bronchial epithelium in two different tissue sections were assessed. Peribronchial blood vessels were identified using immunostaining for vWF. Volumes of blood vessels in the peribronchial compartment (located between the epithelium basement membrane and the alveolar attachments [21]) were also estimated using point counting. Numbers of small (<15 μ m), medium (16–35 μ m) and large (>35 μ m) diameter blood vessels in the peribronchial space were counted for ≥ 10 bronchi (150–300 μ m of internal diameter) at $\times 200$ magnification [21]. Results were expressed as number of vessels per bronchus and as numbers of vessels per surface area of peribronchial compartment (data not shown) [21]. Both methods gave similar results.

Western blot for VEGF protein

Lung homogenates were subjected to electrophoresis and were transferred to polyvinylidene difluoride membrane (Bio-Rad, Marnes-la-Coquette, France). Blots were performed using a rabbit polyclonal Ab to VEGF-A (A-20, 1:1,500; Santa Cruz Biotechnology). Additional information on western blotting is provided in the online supplementary material.

Statistical analysis

Data obtained from *in vitro* experiments are presented as mean \pm SEM of at least three independent experiments performed in duplicate. Data obtained from measurements of VEGF protein concentrations in cultured airway epithelial cells were analysed using one-way ANOVA for repeated measurements followed by the *post hoc* Student–Neuman–Keuls test for multiple comparisons. For *in vivo* experiments, each experiment was performed in a minimum of eight mice per condition. Data obtained from morphometric analyses were analysed using the nonparametric Kruskal–Wallis test followed by the *post hoc* Dunn's test. The

interobserver coefficients of variation for morphometric measurements were <15%. All analyses were performed using the Prism 5 software (GraphPad Inc., La Jolla, CA, USA). Values of $p \leq 0.05$ were considered to indicate statistical significance.

RESULTS

PA supernatants increase VEGF production in human airway epithelial cells

Under baseline conditions, NCI-H292 cells produced low concentrations of VEGF protein (fig. 1). Incubation of the cells with supernatant of the PA laboratory strain PAO1 induced a dose-dependent increase in VEGF protein concentrations (fig. 1a). This increase was three-fold at dilution 1:32 ($p < 0.05$) and went up to five-fold at dilution 1:8 ($p < 0.01$). PAO1 supernatant also increased VEGF synthesis in BEAS-2B cells (by $80 \pm 22\%$ compared with baseline; $n = 6$, $p = 0.01$) and in primary cultures of airway (nasal polyp) epithelial cells at the air–liquid interface (by $28 \pm 8\%$ compared with baseline; $n = 3$, $p = 0.03$; see online supplementary material). Incubation of NCI-H292 cells with supernatants prepared from clinical strains of PA also increased VEGF concentrations ($p < 0.05$ for all strains; fig. 1b).

Next we examined whether secreted products from other bacteria frequently found in subjects with bronchiectasis also induced VEGF synthesis. Supernatants obtained from various strains of *Streptococcus pneumoniae* and *Haemophilus influenzae* induced VEGF synthesis in NCI-H292 cells, whereas *Staphylococcus aureus* supernatants did not induce VEGF production (see online supplementary material).

EGFR signalling pathway is involved in PA-induced VEGF production in NCI-H292 cells

Since EGFR activation by its ligands induces VEGF production in various cell types [12, 22] and because PAO1 supernatant has been shown to activate EGFR in airway epithelium [15], we hypothesised that PA supernatants induced VEGF synthesis *via* EGFR activation. When NCI-H292 cells were pretreated with a selective EGFR tyrosine kinase inhibitor, AG1478 (10 μ M), which prevents EGFR phosphorylation, there was no increase




FIGURE 1. Effects of *Pseudomonas aeruginosa* (PA) supernatants on vascular endothelial growth factor (VEGF) production in NCI-H292 cells. Confluent NCI-H292 cells were cultured in cell culture medium alone (baseline), in the presence of the bacterial culture medium trypticone soy broth dialysate (TSBD; 1:8 dilution) or incubated with PA supernatants for 24 h. VEGF protein concentrations were measured by ELISA in cell culture medium at 24 h. a) Cells were treated with serial dilutions (from 1:32 to 1:8) of PAO1 supernatant. b) Cells were treated with PAO1 supernatant or with supernatants prepared from six different clinical strains of PA (three nonmucooid and three mucooid, labelled 1–6; dilution 1:8). Data are presented as mean \pm SEM (three separate experiments in duplicate). *: $p < 0.05$ compared with baseline; **: $p < 0.01$ compared with baseline.




FIGURE 2. Role of the epidermal growth factor receptor (EGFR) in *Pseudomonas aeruginosa* supernatant-induced vascular endothelial growth factor (VEGF) production in NCI-H292 cells. Confluent NCI-H292 cells were incubated for 24 h with PAO1 supernatant alone (1:8 dilution) or were pretreated with a selective EGFR tyrosine kinase inhibitor (AG1478), an inactive compound (AG9) or an EGFR-neutralising antibody (EGFR Ab). VEGF protein concentrations were measured by ELISA in cell culture medium at 24 h. **: $p < 0.01$ compared with baseline; #: $p < 0.01$ compared with PAO1 supernatant alone.

in VEGF concentrations upon incubation with PAO1 supernatant ($p < 0.01$; fig. 2). Pretreatment with AG9 (10 μ M; an inactive analogue of AG1478) was without effect. PAO1 supernatant-induced VEGF production was also prevented by

pre-incubation with an EGFR-neutralising Ab ($p < 0.01$; fig. 2), but not with an irrelevant Ab (data not shown).

Persistent PAO1 airway infection induces VEGF expression in the airway epithelium in mice

In control mice (no instillation), immunostaining for VEGF was weak and localised to airway epithelium (fig. 3). In mice that received intratracheal instillation of sterile agarose beads, a weak immunostaining for VEGF was observed in the airway epithelium at day 1 and day 7 after instillation (fig. 3). By contrast, in mice instilled with PAO1-coated beads, resulting in persistent airway infection at day 7 (see Methods), an increase in VEGF immunostaining was observed in the airway epithelium at both day 1 and day 7 after instillation (fig. 3). Morphometric analysis indicated a significant 1.5-fold increase in epithelial VEGF staining at day 7 ($p < 0.05$ compared with control mice and $p < 0.05$ compared with mice instilled with sterile beads; fig. 4a). VEGF protein expression was further examined by western blot in mouse lung homogenates. Results confirmed that VEGF expression was increased at day 7 in lungs of mice instilled with PAO1-coated beads (fig. 4b and c).

Role of EGFR activation in VEGF expression in mouse airway epithelium in vivo

As our *in vitro* studies demonstrated that VEGF synthesis upon PA supernatant stimulation was dependent on EGFR activation, we studied phosphorylated (activated) EGFR in mouse bronchial epithelium. In control mice, epithelial staining for




FIGURE 3. Representative photomicrographs of immunostaining for vascular endothelial growth factor (VEGF) and phosphorylated epidermal growth factor receptor (p-EGFR) in control mice, and in mice instilled with sterile beads or with beads coated with the *Pseudomonas aeruginosa* strain PAO1. Airway tissue sections were obtained from mice without instillation (control), and after 1 day and 7 days in mice that received intratracheal instillation of beads (B). Sections were stained with antibodies to VEGF (a and b) and to p-EGFR (c) and were counterstained with haematoxylin. In control mice, weak or no staining for VEGF and p-EGFR was present in the epithelium. Instillation of sterile beads only resulted in a small increase in VEGF staining in the epithelium at day 7. However, instillation of PAO1-coated beads induced a marked increase in VEGF and p-EGFR staining (brown staining) in the epithelium. a) At low magnification, airway epithelium appears as a major site of VEGF expression after PAO1 infection. b) Higher magnification shows granular staining for VEGF throughout the epithelium after PAO1 infection, which also resulted in the recruitment of numerous inflammatory cells (mostly neutrophils; arrows) in the airway lumen and in the adjacent alveoli (arrowheads). Results obtained in at least eight animals per condition. Scale bars=50 μ m. Original magnifications: a) $\times 100$; b and c) $\times 400$.




FIGURE 4. Effects of infection with the *Pseudomonas aeruginosa* strain PAO1 on vascular endothelial growth factor (VEGF) expression and epidermal growth factor receptor (EGFR) phosphorylation in mouse airways. Mice were sacrificed without instillation (control), and 1 day and 7 days after intratracheal instillation of sterile or PAO1-coated beads. In some experiments, mice were pretreated with the selective EGFR tyrosine kinase inhibitor AG1478 (12.5 mg·kg⁻¹·day⁻¹ intraperitoneally) or with vehicle (dimethyl sulfoxide; DMSO), 24 h before instillation and daily until sacrifice at day 7. a) Airway sections were immunostained for VEGF protein and morphometric analysis of VEGF immunostaining in airway epithelium was performed. b) Representative western blot for VEGF protein in lung homogenates. Membranes were stripped and reprobed with an antibody to β-actin to normalise for protein loading. c) Quantification of relative VEGF protein levels in western blots of lung homogenates. d) Airway sections were immunostained for phosphorylated EGFR (p-EGFR) and morphometric analysis of p-EGFR immunostaining in airway epithelium was performed. Data are presented as mean ± SEM from at least eight mice per condition for morphometric analysis and four mice per condition for western blotting. *: p<0.05 compared with control; **: p<0.01 compared with control; #: p<0.01 compared with sterile beads at day 7; †: p<0.01 compared with PAO1-coated beads at day 7.

phosphorylated EGFR was low (figs 3 and 4d). Similarly, in mice that received intratracheal instillation of sterile beads, epithelial staining for phosphorylated EGFR was low and did not change between day 1 and day 7 after instillation (figs 3 and 4d). By contrast, whereas staining for phosphorylated EGFR was low at day 1 in the epithelium of mice instilled with PAO1-coated beads, a significant two-fold increase was observed at day 7 (p<0.01 compared with control mice; p<0.01 compared with mice instilled with sterile beads; figs 3 and 4d).

To further examine the role of EGFR activation in VEGF airway epithelial expression in mice upon instillation with PAO1-coated beads, mice were treated with the EGFR tyrosine kinase inhibitor AG1478 (12.5 mg·kg⁻¹·day⁻¹ intraperitoneally) or with vehicle, before intratracheal instillation of PAO1-coated beads and daily until sacrifice at day 7. There was no difference in phosphorylated EGFR expression between mice instilled with PAO1-coated beads and treated with vehicle, and mice that were only instilled

with PAO1-coated beads (fig. 4d). As expected, treatment with AG1478 resulted in a very low phosphorylated EGFR staining in the airway epithelium (p<0.01 compared with mice that were instilled with PAO1-coated beads and treated with vehicle alone; fig. 4d). When expression of VEGF was studied, there was no difference in VEGF expression between mice instilled with PAO1-coated beads and treated with vehicle, and mice that were only instilled with PAO1-coated beads (fig. 4a). However, VEGF staining in airway epithelium was reduced by two-fold in mice treated with the EGFR inhibitor (p<0.001 compared with mice that were instilled with PAO1-coated beads and treated with vehicle; fig. 4a).

Persistent PAO1 airway infection induces peribronchial angiogenesis in mice

As epithelial VEGF is an angiogenic factor for airway blood vessels [8], we next examined whether instillation of PAO1-coated beads resulted in peribronchial angiogenesis. Blood

vessels in the peribronchial compartment were studied using the endothelial marker vWF. Morphometric analysis of volume occupied by vWF staining in the peribronchial compartment showed no significant difference between control mice and mice instilled with sterile or PAO1-coated beads (data not shown). A morphometric analysis was then performed that differentiated between small (<15 μm), medium (16–35 μm) and large (>35 μm) peribronchial blood vessels as described by LEE *et al.* [21] (see Methods). Instillation of sterile beads had no effect on blood vessel counts according to their size. In contrast, instillation of PAO1-coated beads resulted in a marked increase in small blood vessels counts at day 7, whereas no effect was observed on medium and large vessel counts (fig. 5a and b). Treatment of mice with AG1478 reduced, but did not abolish, the increase in small blood vessel numbers in mice instilled with PAO1-coated beads.

DISCUSSION

Our results show VEGF synthesis by airway epithelial cells upon PA stimulation both *in vitro* and *in vivo*. PA-induced

VEGF synthesis was associated *in vivo* with increased numbers of small peribronchial blood vessels. Administration of EGFR inhibitors reduced PA-induced VEGF synthesis in cultured airway epithelium and in mouse airway epithelium, and reduced the increase in small peribronchial vessels *in vivo*.

VEGF has been shown to be expressed by alveolar type II cells, airway epithelial cells, smooth muscle cells, fibroblasts and alveolar macrophages [7]. In our study, under baseline conditions, VEGF synthesis by bronchial epithelial cells was low, both *in vitro* and in mice. This is in accordance with previously published studies: LEE *et al.* [23] have shown low levels of VEGF expression in normal human bronchial epithelial cells under basal conditions and CORNE *et al.* [24] have found low expression of VEGF in the bronchial epithelium of C57BL/6 mice. However, upon incubation in the presence of PA supernatants *in vitro* or in the presence of persistent PAO1 infection *in vivo*, we observed that VEGF synthesis by airway epithelial cells markedly increased. Although VEGF was expressed in other cell types (*e.g.* macrophages; data not shown), these data




FIGURE 5. Effects of airway infection with the *Pseudomonas aeruginosa* strain PAO1 on peribronchial blood vessels in mice. Airway tissue sections were obtained from mice without instillation (control), and 1 day and 7 days after intratracheal instillation of sterile or PAO1-coated beads. In some experiments mice were pretreated with AG1478 (12.5 $\text{mg}\cdot\text{kg}^{-1}\cdot\text{day}^{-1}$ intraperitoneally) or with vehicle, 24 h before instillation and daily until sacrifice at day 7. a) Representative photomicrographs of immunostaining for von Willebrand factor (vWF), an endothelial marker for identification of peribronchial blood vessels (brown colour). Although large (L) and medium (M) blood vessels are present adjacent to airways in control and in instilled animals, only animals instilled with PAO1-coated beads have numerous small peribronchial blood vessels (arrowheads). Scale bar=50 μm . Original magnification $\times 200$. b) Small (<15 μm), medium (16–35 μm) and large (>35 μm) vWF-positive peribronchial blood vessels were counted as described previously [21]. Data are presented as mean \pm SEM from at least eight mice per condition. ***: $p < 0.001$ compared with control; #: $p < 0.05$ compared with mice instilled with sterile beads.

implicate airway epithelium as a major site of VEGF synthesis after bacterial stimulation.

Our study is the first to show, *in vitro* and *in vivo*, increased VEGF synthesis by airway epithelial cells upon exposure to PA. It is strengthened by the fact that both the laboratory strain PAO1 and several clinical PA strains induced VEGF expression *in vitro*. Our data are consistent with the report of increased VEGF synthesis by chondrocytes after a 6-h exposure to PA supernatants [25]. In the latter study, the authors also reported induction of VEGF synthesis in chondrocytes exposed to *S. aureus* supernatants (but no information on bacterial strains was provided) [25], whereas in the present study, various strains of *S. aureus* were without effect on VEGF synthesis in airway epithelium. These differences may be related to different behaviour of airway epithelial cells *versus* chondrocytes or to different bacterial strains. Importantly, infectious agents other than PA may also enhance VEGF synthesis in airway epithelium. We found that *S. pneumoniae* and *H. influenzae* supernatants induced VEGF synthesis in cultured airway epithelial cells (see online supplementary material). Furthermore, the respiratory syncytial virus has been shown to stimulate VEGF synthesis *in vitro* in airway epithelial cells and *in vivo* in nasal secretions in patients [23]. Taken together, these data support the concept that airway infection may be associated with increased VEGF expression in airway epithelium.

The present study was not designed to identify specifically which products in PA supernatants were responsible for EGFR activation and VEGF synthesis. We found that PA-induced VEGF synthesis persisted when PAO1 supernatant was boiled or treated with proteases before incubation with epithelial (NCI-H292) cells (C. Martin and P-R. Burgel; unpublished data). Although PA lipopolysaccharide (LPS) induced VEGF synthesis in NCI-H292 epithelial cells dose dependently, we found no effect of PA-LPS on VEGF synthesis in BEAS-2B cells or in primary cultures of airway epithelial cells (see online supplementary material). These latter findings are consistent with the report by MURPHY *et al.* [26], who found no effect of LPS on VEGF synthesis in primary cultures of airway epithelial cells derived from lung allograft. Further studies will be necessary to identify soluble products responsible for PA-induced VEGF synthesis in airway epithelium.

We found that PA-induced VEGF synthesis *in vivo* and *in vitro* was dependent, at least partly, on EGFR activation. Mechanisms leading from bacterial stimuli to EGFR activation require discussion. The airway epithelium is the first line of defence against invading pathogens and senses bacterial signals *via* cognate receptors (*e.g.* Toll-like receptors (TLRs)) [11]. KOFF *et al.* [27] have recently shown that activation of various TLRs by their recombinant ligands induced VEGF synthesis in cultured airway epithelial cells *via* a cascade of events culminating in EGFR activation, but the role of specific bacterial stimuli was not studied. Interestingly, VAROGA *et al.* [25] have shown that activation of TLR2 by *S. aureus* supernatant resulted in extracellular signal-regulated (ERK)1/2-dependent VEGF synthesis in cultured human chondrocytes, but the role of EGFR activation in this process was not explored. We speculate that TLRs play a role in PA-induced EGFR activation and VEGF synthesis, but further studies will be required to establish these mechanisms.

The number of small peribronchial vessels had increased 7 days after instillation of PAO1-coated beads. This time-course is consistent with previous studies that showed that 7 days after intranasal inoculation of *Mycoplasma pulmonis* in various strains of mice, modifications in tracheal microvasculature and endothelial cell proliferation occurred [28, 29]. This rapid angiogenesis was also observed in the absence of bacterial stimulation. In a tet-on transgenic mouse model in which VEGF was selectively overexpressed in the airway epithelium under the control of a tissue-specific promoter, endothelial sprouting was observed 1 day after switching on VEGF expression, and a two-fold increase in vessel density had occurred by day 7 [8]. Although these data show that angiogenesis is a rapid process, we suggest that longer studies may more closely mimic vascular abnormalities occurring in chronically infected airways in humans with bronchiectasis.

The overexpression of VEGF in airway epithelium following PA infection *in vivo* suggests that PA-induced peribronchial angiogenesis is mediated by interaction between epithelial VEGF and endothelial VEGF receptors. However, multiple proangiogenic molecules (*e.g.* growth factors and cytokines) may play a role in PA-induced peribronchial angiogenesis [30], and studies using VEGF receptor antagonists will be required to confirm the role of VEGF. Additionally, although increased peribronchial vascularity induced by PA was reduced by EGFR inhibition, the exact role of EGFR in this process was not determined. This could be due to a direct effect of the EGFR antagonist on endothelial cells or to an indirect effect related to reduction of VEGF synthesis in airway epithelium.

Our report is the first to experimentally show a relationship between bronchial infection with PA and peribronchial angiogenesis. It suggests a role for chronic airway infection in the development of the abnormal bronchial circulation, containing multiple tortuous and hypertrophic blood vessels, which is found in subjects with bronchiectasis. We speculate that intensive antibiotic therapy against persistent bacterial infection may help to reduce abnormalities in the bronchial circulation in patients with bronchiectasis.

In conclusion, we have shown that exposure of airway epithelium to PA products increased expression of VEGF synthesis *in vitro* and *in vivo*, at least in part *via* EGFR activation. PA-induced VEGF synthesis was associated with rapid peribronchial angiogenesis. We suggest that the effects of EGFR inhibitors in reducing bronchial angiogenesis in chronic airway inflammatory diseases (*e.g.* bronchiectasis) need to be further examined in humans. Ultimately, it may prove a useful approach for reducing angiogenesis triggered by persistent bacterial infection.

SUPPORT STATEMENT

This work was funded by grants from Chancellerie des Universités de Paris (Legs Poix), Association Vaincre la Mucoviscidose and Association Cardiff (all Paris, France).

STATEMENT OF INTEREST

None declared.

ACKNOWLEDGEMENTS

The authors thank J.A. Nadel (Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA), E. Escudier (INSERM, Unit U955, Creteil, France) and A. Coste (Dept of

Otolaryngology – Head and Neck Surgery, Hôpital Intercommunal de Créteil) for helpful discussions. We thank J-F. Papon (Dept of Otolaryngology – Head and Neck Surgery, Hôpital Intercommunal de Créteil) and A. Coste for providing primary cultures of nasal airway epithelial cells.

REFERENCES

- 1 Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. *Thorax* 2010; 65: Suppl. 1, i1–i58.
- 2 Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. *Eur Respir J* 2008; 31: 396–406.
- 3 Nicotra MB, Rivera M, Dale AM, et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. *Chest* 1995; 108: 955–961.
- 4 Charan NB, Baile EM, Pare PD. Bronchial vascular congestion and angiogenesis. *Eur Respir J* 1997; 10: 1173–1180.
- 5 Paredi P, Barnes PJ. The airway vasculature: recent advances and clinical implications. *Thorax* 2009; 64: 444–450.
- 6 Ribatti D. The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. *Br J Haematol* 2005; 128: 303–309.
- 7 Mura M, dos Santos CC, Stewart D, et al. Vascular endothelial growth factor and related molecules in acute lung injury. *J Appl Physiol* 2004; 97: 1605–1617.
- 8 Baluk P, Lee CG, Link H, et al. Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial factor in airways. *Am J Pathol* 2004; 165: 1071–1085.
- 9 Koyama S, Sato E, Tsukadaira A, et al. Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines *in vitro*. *Eur Respir J* 2002; 20: 1449–1456.
- 10 van Heeckeren AM, Schluchter MD. Murine models of chronic *Pseudomonas aeruginosa* lung infection. *Lab Anim* 2002; 36: 291–312.
- 11 Burgel PR, Nadel JA. Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases. *Eur Respir J* 2008; 32: 1068–1081.
- 12 Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells *in vitro* and *in vivo*: angiogenic implications for signal transduction therapy of solid tumors. *Am J Pathol* 1997; 151: 1523–1530.
- 13 Coste A, Brugel L, Maitre B, et al. Inflammatory cells as well as epithelial cells in nasal polyps express vascular endothelial growth factor. *Eur Respir J* 2000; 15: 367–372.
- 14 Massion PP, Inoue H, Richman-Eisenstat J, et al. Novel *Pseudomonas* product stimulates interleukin-8 production in airway epithelial cells *in vitro*. *J Clin Invest* 1994; 93: 26–32.
- 15 Shao MX, Ueki IF, Nadel JA. Tumor necrosis factor α -converting enzyme mediates MUC5AC mucin expression in cultured human airway epithelial cells. *Proc Natl Acad Sci USA* 2003; 100: 11618–11623.
- 16 Ishii Y, Fujimoto S, Fukuda T. Gefitinib prevents bleomycin-induced lung fibrosis in mice. *Am J Respir Crit Care Med* 2006; 174: 550–556.
- 17 Burgel PR, Cardell LO, Ueki IF, et al. Intranasal steroids decrease eosinophils but not mucin expression in nasal polyps. *Eur Respir J* 2004; 24: 594–600.
- 18 Burgel PR, Montani D, Danel C, et al. A morphometric study of mucins and small airway plugging in cystic fibrosis. *Thorax* 2007; 62: 153–161.
- 19 Brusasco V, Dinh-Xuan AT. Stereology: a bridge to a better understanding of lung structure and function. *Eur Respir J* 2010; 35: 477–478.
- 20 Hsia CC, Hyde DM, Ochs M, et al. An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. *Am J Respir Crit Care Med* 2010; 181: 394–418.
- 21 Lee SY, Cho JY, Miller M, et al. Immunostimulatory DNA inhibits allergen-induced peribronchial angiogenesis in mice. *J Allergy Clin Immunol* 2006; 117: 597–603.
- 22 Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. *Clin Cancer Res* 1999; 5: 257–265.
- 23 Lee CG, Yoon HJ, Zhu Z, et al. Respiratory syncytial virus stimulation of vascular endothelial cell growth factor/vascular permeability factor. *Am J Respir Cell Mol Biol* 2000; 23: 662–669.
- 24 Corne J, Chupp G, Lee CG, et al. IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury. *J Clin Invest* 2000; 106: 783–791.
- 25 Varoga D, Paulsen F, Mentlein R, et al. TLR-2-mediated induction of vascular endothelial growth factor (VEGF) in cartilage in septic joint disease. *J Pathol* 2006; 210: 315–324.
- 26 Murphy DM, Forrest IA, Corris PA, et al. Azithromycin attenuates effects of lipopolysaccharide on lung allograft bronchial epithelial cells. *J Heart Lung Transplant* 2008; 27: 1210–1216.
- 27 Koff JL, Shao MX, Ueki IF, et al. Multiple TLRs activate EGFR *via* a signaling cascade to produce innate immune responses in airway epithelium. *Am J Physiol Lung Cell Mol Physiol* 2008; 294: L1068–L1075.
- 28 Ezaki T, Baluk P, Thurston G, et al. Time course of endothelial cell proliferation and microvascular remodeling in chronic inflammation. *Am J Pathol* 2001; 158: 2043–2055.
- 29 Thurston G, Murphy TJ, Baluk P, et al. Angiogenesis in mice with chronic airway inflammation: strain-dependent differences. *Am J Pathol* 1998; 153: 1099–1112.
- 30 Szekanecz Z, Besenyei T, Paragh G, et al. Angiogenesis in rheumatoid arthritis. *Autoimmunity* 2009; 42: 563–573.